AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy

4Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$271Upside to Avg. PT-5.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	RBC Capital	Trung Huynh	Maintained	Outperform	$280
Oct 9, 2026	UBS	Michael Yee	PT Raise	Neutral	$260→$275
Oct 9, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$288
Oct 8, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$285→$300
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$285→$290
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$296→$310
Oct 6, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$280→$320
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$300→$315
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$298→$303
Aug 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$295→$300
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 11, 2026	BNP Paribas	Navann Ty	PT Raise	Neutral	$218→$247
Aug 10, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$246→$260
Aug 6, 2026	Berenberg	Luisa Hector	Maintained	Buy	$275
Aug 5, 2026	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 4, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$261→$288
Aug 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$278→$296
Aug 3, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$282→$290
Aug 3, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$265→$285
Jul 31, 2026	TD Cowen	Steve Scala	Maintained	Buy	$280